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Abstract
Low back pain is a common and costly condition and
for most people is likely to be a recurrent problem
throughout their lifetime. The management of
patients with low back pain has been positively
influenced by the rise in high quality clinical trials and
systematic reviews in recent decades, and this body
of evidence, synthesized in many clinical practice
guidelines, has improved our knowledge about which
treatments for low back pain are useful and which are
not. For the largest group of patients, those with non-
specific low back pain for whom a clear diagnosis
cannot be given, the reality is that the treatments we
have to offer tend to produce small effects, often only
in the short term and none appear to effectively
change long-term prognosis. This commentary
summarizes the array of treatments currently available,
notes the results of recent trials and guidelines and
considers alternative approaches that may prove
more valuable in achieving better patient outcomes
in the future.
Introduction
Nearly everyone gets low back pain (LBP) at least once in
their lifetime making the effective treatment of this com-
mon complaint of widespread interest. It is the most com-
mon reason for middle-aged people to visit their family
doctor [1] with approximately 6% to 9% of adults consult-
ing for this condition each year [1,2]. Although many LBP
patients stop consulting within three months, 60% to 80%
of people still report pain or disability a year later, and up
to 40% of those who have taken time off work will have
future episodes of work absence [3,4]. Hence, previous
ideas of acute (less than four weeks), sub-acute (four
weeks to 12 weeks) and chronic LBP (more than 12
weeks) are gradually being superseded by the view of LBP
as a chronic, recurrent condition with an untidy pattern of
symptomatic episodes, remissions and recurrences [3].
Dunn and colleagues [5] proposed four trajectories for
LBP patients representing different paths over time; persis-
tent mild, recovering, severe chronic and fluctuating, paths
that have been since confirmed in other samples [6]. The
societal cost of LBP-related work absence is considerable.
Patients with LBP account for more than $90 billion
annually in health care expenses in the US [7] and $9.17
billion in total costs in Australia [8]. In the UK, costs are
i nt h er e g i o no f1 %t o2 %o fg r o s sn a t i o n a lp r o d u c t[ 9 ]
with National Health Service (NHS) costs alone of £251
million annually [10].
Recent years have seen an exponential increase in
research focused on LBP and early criticisms about poor
quality studies have largely been addressed by recent
trials using rigorous methodology [11-14]. Many prac-
tice guidelines [15-17] are now available to help practi-
tioners choose treatments that are safe and effective. A
sobering reflection however is that no treatment has
large, significant and consistent benefits for patients
with non-specific LBP. Despite decades of research and
improved quality of clinical trials, the reality is that the
treatments we have to offer patients tend to produce
small effects, often only in the short term and none
appear to change effectively the longer-term prognostic
paths or trajectories for patients.
In this commentary I will discuss the variety of cur-
rent treatment options and recent guideline recommen-
dations, then consider the trends in results of recent
high quality trials and the potential explanations for
them before suggesting key alternative approaches of
potentially more value in achieving better patient out-
comes in the future.
Discussion
Current treatment options and guideline
recommendations
There is an almost endless list of treatment options cur-
rently available to patients with LBP, each supported by
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rationales and research evidence. Some are accompanied
by extravagant claims of complete pain relief, often
advertised via the internet [18]. Most of these claims
and unusual treatment approaches have not proven to
be effective when subjected to rigorous and independent
evaluation [19]. Treatments include oral medications,
topical medications, exercise, manual therapy, traction,
acupuncture, transcutaneous electrical nerve stimulation
(TENS), spinal cord stimulators, mattresses, orthotics,
back supports, biofeedback, spinal injections and sur-
gery. In other words, LBP patients may be offered treat-
ments from the full range of conservative,
pharmacological, non-pharmacological, traditional and
complementary healthcare interventions as well as inva-
sive interventions.
Given this almost limitless array of options, it is not
uncommon for patients with similar LBP signs and
symptoms to receive different interventions from health-
care professionals. Key reasons for such variation in
practice [20,21] are firstly, the close commitment of dif-
ferent intervention providers to their respective favorite
treatments and secondly, the clinical uncertainty asso-
ciated with LBP, in terms of diagnosis, prognosis and
treatment selection. Evidence for the first reason is pro-
vided by studies that show the association between the
attitudes and beliefs of practitioners and their clinical
behaviors for patients with LBP [21]. As for the second
reason, we know that the serious pathologies such as
cancer, infection and inflammatory disease account for
less than one percent of LBP cases, nerve root problems
(associated with radiculopathy or spinal stenosis) are
thought to explain no more than 10% to 15% of cases,
whereas most LBP (an estimated 85%) is suggested to be
‘non-specific’, resulting in three diagnostic groups. Given
that the term ‘non-specific LBP’ most likely refers to
many LBP problems with different etiologies, ensuring
‘the right patient gets the right treatment at the right
time’ is a particular challenge. While imaging seems a
logical way to resolve this dilemma, the use of early
magnetic resonance imaging (MRI) scans does not alter
patients’ outcomes and are actually associated with per-
sistent perceptions of poor health [22].
More than 2,500 controlled trials of treatments for
back and neck pain listed in the Cochrane database, 32
Cochrane systematic reviews of randomized trials, 13
recent national clinical guidelines and two international
guidelines from Europe have led to general agreement
about best practice for non-specific LBP around the
world [23]. This starts with the provision of information
about the expected course of the problem and self-care
options that patients should try, early and gradual return
to normal activities including work, discouragement of
bed rest as a treatment, avoidance of routine imaging,
use of first line medications (starting with time-contin-
gent acetaminophen and progressing to non-steroidal
anti-inflammatory drugs if needed), and the assessment
of psychosocial risk factors for chronicity (although the
detail of how best to do this varies considerably between
available guidelines). The use of passive treatments such
as electrotherapy and therapeutic ultrasound is generally
discouraged. As LBP persists, best practice recommen-
dations include non-pharmacological therapies with pro-
ven benefits; supervised exercise, manual therapy,
acupuncture, cognitive behavioral therapy with intensive
multidisciplinary treatments reserved for those who do
not benefit from these approaches [16,17,23]. The con-
tent of recent guidelines, irrespective of country, is
broadly similar regarding the diagnostic classification
( t h ed i a g n o s t i ct r i a g eo u t l i n e da b o v e )a n dt h eu s eo f
diagnostic and therapeutic interventions with some dis-
crepancy around the use of spinal manipulation and
some stronger medications [23].
Why aren’t treatments more effective?
There are likely several key explanations, explored in
detail elsewhere [19,24]. Firstly, many of our current
treatments are predicated on a healthcare practitioner’s
specific diagnosis, based on for example imaging find-
ings or the results of subjective and objective examina-
tion, yet these approaches to diagnosis correlate poorly
with the patient’s symptoms [19], their onward path or
trajectory, or their treatment responsiveness. Secondly,
patient heterogeneity in clinical trials means that the
average treatment effect masks a wide range of indivi-
dual responses to any specific treatment, including for
example, patients who benefit a great deal along with
t h o s ew h ob e n e f i tl i t t l eo rn o ta ta l l[ 2 4 ] .T h u sac o m -
pelling argument for our lack of progress in achieving
better treatment results is th a tw eh a v ef a i l e dt of o c u s
on identifying and addressing the factors that really do
influence patients’ outcomes [19]. In other words, we
have largely failed to match patients with the most
appropriate treatment for their individual profile. Identi-
fication of clinically relevant subgroups of non-specific
LBP patients may be related to causal mechanisms, dif-
ferent prognoses or treatment responsiveness. For exam-
ple, although psychosocial factors associated with poor
prognosis (or yellow flags) have been shown to be
important in the development of chronicity and future
disability [25,26] and most guidelines recommend the
assessment of these factors, there have been few easy-
to-use tools to help clinicians identify these factors in
busy clinical practice and limited guidance about appro-
priate treatment for patients in whom these factors are
identified. Although healthcare professionals often feel
they can intuitively identify the patients with LBP who
have a poor prognosis, actually these patients are often
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estimations about LBP patients when using intuition
alone [27]. More individual and accurate estimates of
the prognosis of patients are needed so that we might
better target the treatments we offer to those who need
them [23]. Several clinical tools exist to aid healthcare
professionals in identifying patients either at risk of
chronicity or to improve targeting of treatment, sum-
marized in Hill et al. [28]. One of the most widely used
is the 24-item Örebro Musculoskeletal Pain Screening
Questionnaire which is still rather long for use in busy
clinical practice. A recently validated tool to identify risk
subgroups of LBP patients is the shorter nine item
STarT Back Tool [29] which has been shown to have
similar properties to the Örebro instrument but is easier
for patients to complete and professionals to score [28].
A second compelling explanation for the generally
poor outcomes seen in usual practice such as primary
care settings [25] is the limited way in which best evi-
dence recommendations have been translated into
everyday clinical practice for patients with LBP. For
example, we know that early access to advice and infor-
mation about self-management and some specific treat-
ments such as exercise, manual therapy, acupuncture
and cognitive-behavioral interventions are effective, yet
most patients in primary care actually receive sympto-
matic care through advice related to the current episode
and medication alone, neither of which has a clear focus
on secondary prevention. Another example is return to
work advice, where just under a third of healthcare
practitioners continue to recommend staying off work
to patients for whom guideline recommendations sug-
gest the opposite [21]. Reasons why adherence to guide-
line recommendations for work might be less than ideal
are unclear, but may be, in part, due to the complex
nature of the clinical consultation, in which healthcare
professionals such as general practitioners (GPs) want to
tailor their decisions according to a patient’s individual
expectations and demands and thus place higher relative
importance on maintaining a good long term relation-
ship with their patient rather than adhering to guideline
recommendations. Confronting patients about sickness
certification may therefore be seen as a potential threat
to the practitioner-patient relationship by some GPs
while for others, they may feel they are not best placed
to judge whether a LBP patient can return to work
safely.
Potentially more effective approaches and future
directions
There are at least two avenues that may provide better
progress on the road to improving the outcomes of this
patient group. One requires a clearer focus on the fac-
t o r st h a ti n f l u e n c eL B Po u t c o m es ow ec a nu s et h a t
information to test different approaches to subgrouping
or screening LBP patients for targeted treatment. This is
one of the research recommendations in the recent
National Institute of Health and Clinical Excellence
guidelines for LBP in the UK [17]. There are promising
developments in this field [27-33], with one such exam-
ple involving a change in the focus of treatment from
symptomatic relief only to secondary prevention and
reducing the risk of future recurrences and chronicity
[29,34]. Patients with poorer physical function and those
with psychological obstacles to recovery such as psycho-
logical distress, negative feelings about their back pain
and increased fear of activity, are more disabled by their
pain and are more likely to have a poor outcome [17].
A potentially more effective system would be one in
which there is early identification of patients at risk of
chronicity and subsequently efforts to prevent such
chronicity [35]. Addressing these factors in primary care
at an early stage before they become entrenched and
more difficult to treat could lead to better long term
outcomes. Prognostic assessment tools, in primary care,
identifying subgroups of patients at risk of persistent
LBP, and who may benefit from interventions that target
key physical and/or psychological obstacles to recovery
have been developed and validated. One example of this
is the STarT Back tool [29]. Specifically designed for
primary care settings, the STarT Back tool is a sub-
grouping instrument that classifies patients into three
categories for targeted treatment, based on the presence
of modifiable risk factors for poor outcome. A rando-
mized controlled trial (the STarT Back trial) is testing
whether subgrouping for targeted treatment is better
than best current care (provided by physiotherapists) of
non-targeted treatment [34]. This potentially more effec-
tive treatment strategy is an example of a move towards
stratified healthcare and away from the one-size-fits-all
approach, improving the odds of getting the right
patient to the right treatment at the right time.
Perhaps a less exciting but no less challenging
approach to improving outcomes for patients with LBP
is to invest much more effort in translating best practice
recommendations from high quality research into every-
day clinical practice. Such approaches are likely to need
to include not only patients as targets for the interven-
tion but also the healthcare practitioners and organiza-
tional processes involved in their care. Several studies
have attempted to change healthcare practitioner beha-
vior for LBP patients [36-44] and overall highlight the
considerable challenges and generally small effects of
implementation efforts to date. Targeting the general
public through mass media campaigns about LBP has
shown promise [45-47] and the benefit of this type of
approach is the way in which the intervention also tar-
gets healthcare practitioners. Finding better incentives
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how public policy can help are both likely to be useful.
The cost burden of LBP to society means that research
that more carefully develops and tests ways to better
support the translation of best practice into everyday
clinical practice is a clear priority.
Conclusions
Despite the plethora of treatments for LBP patients, and
the production of multiple guidelines for practice, get-
ting the right patient to the right treatment at the right
time is still a considerable challenge. Findings from epi-
demiological studies and recent high quality trials
underline the need to consider seriously the following
t w oa v e n u e so fp r o g r e s s .F i r s t l y ,am o v ea w a yf r o ma
one-size-fits-all approach to LBP and towards greater
subgrouping for targeted treatment in LBP, and sec-
ondly, more considerable effort to support the transla-
tion of best practice and provision of treatments with
clear evidence of effectiveness into clinical reality for
patients.
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